Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serology-based therapeutic strategy in SARS-CoV-2-infected patients.
Garcia-Muñoz R, Farfán-Quiroga G, Ruiz-de-Lobera N, Feliu J, Anton-Remirez J, Nájera Irazu MJ, Lisa Catón V, Oteo-Revuelta JA. Garcia-Muñoz R, et al. Among authors: feliu j. Int Immunopharmacol. 2021 Dec;101(Pt B):108214. doi: 10.1016/j.intimp.2021.108214. Epub 2021 Oct 5. Int Immunopharmacol. 2021. PMID: 34649116 Free PMC article.
Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia.
García-Muñoz R, Aguinaga L, Feliu J, Anton-Remirez J, Jorge-Del-Val L, Casajús-Navasal A, Nebot-Villacampa MJ, Daroca-Fernandez I, Domínguez-Garrido E, Rabasa P, Panizo C. García-Muñoz R, et al. Among authors: feliu j. Immunotherapy. 2018 Mar 1;10(6):491-499. doi: 10.2217/imt-2017-0147. Immunotherapy. 2018. PMID: 29562857
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.
García-Muñoz R, Nájera MJ, Feliu J, Antón-Remírez J, Ramalle-Gómara E, Marín-Gorricho R, Peralta R, Gutiérrez-Gamarra E, Nuñez-Rodriguez J, Zafra-Morales R, Aguinaga L, Nebot-Villacampa MJ, Hernandez-Pérez PM, Farfán-Quiroga G, Panizo C, Domínguez-Garrido E. García-Muñoz R, et al. Among authors: feliu j. Future Sci OA. 2019 Nov 26;5(10):FSO425. doi: 10.2144/fsoa-2019-0064. Future Sci OA. 2019. PMID: 31827894 Free PMC article.
Peripheral blood natural killer cell depletion is associated with severe pneumonia in coronavirus disease-2019 (COVID-19).
Garcia-Muñoz R, Feliu J, Anton-Remirez J, Metola L, Sosa-Campos E, Sanz MP, Farfan G, Labrador-Sanchez E, Ibarra V, Peña JL, Pascual A, Hermosa MJ, Blasco M, Llerena-Garcia L, Najera MJ, Oteo JA. Garcia-Muñoz R, et al. Among authors: feliu j. Ir J Med Sci. 2022 Jun;191(3):1453-1455. doi: 10.1007/s11845-021-02701-4. Epub 2021 Jul 2. Ir J Med Sci. 2022. PMID: 34215960 Free PMC article. No abstract available.
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
García-Muñoz R, López-Díaz-de-Cerio A, Feliu J, Panizo A, Giraldo P, Rodríguez-Calvillo M, Grande C, Pena E, Olave M, Panizo C, Inogés S. García-Muñoz R, et al. Among authors: feliu j. Immunol Res. 2016 Apr;64(2):548-57. doi: 10.1007/s12026-015-8747-9. Immunol Res. 2016. PMID: 26659089
GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race.
García-Muñoz R, Anton-Remirez J, Nájera MJ, Gutierrez-Gamarra E, Peralta R, Feliu J. García-Muñoz R, et al. Among authors: feliu j. Future Sci OA. 2019 Feb 12;5(3):FSO375. doi: 10.4155/fsoa-2018-0122. eCollection 2019 Mar. Future Sci OA. 2019. PMID: 30906570 Free PMC article. No abstract available.
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
López-Díaz de Cerio A, García-Muñoz R, Pena E, Panizo Á, Feliu J, Giraldo P, Rodríguez-Calvillo M, Martínez-Calle N, Grande C, Olave MT, Andrade-Campos M, Bandrés E, Núñez-Córdoba JM, Inogés S, Panizo C. López-Díaz de Cerio A, et al. Among authors: feliu j. Br J Haematol. 2020 Jun;189(6):1064-1073. doi: 10.1111/bjh.16474. Epub 2020 Mar 4. Br J Haematol. 2020. PMID: 32130737 Free article. Clinical Trial.
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI).
Feliu J, Potter V, Grimaldi F, Clay J, Floro L, Saha C, Barber L, Orti G, Alnagar AA, Garcia-Muñoz R, Kenyon M, Krishnamurthy P, de Lavallade H, Raj K, McLornan D, Pagliuca A, Mufti GJ. Feliu J, et al. Bone Marrow Transplant. 2020 Mar;55(3):562-569. doi: 10.1038/s41409-019-0695-x. Epub 2019 Sep 26. Bone Marrow Transplant. 2020. PMID: 31558789
482 results